Table 2.
Virus co-findings in the IgG4-positive group, the IgG4-negative group, and the control group comprising of samples representing healthy salivary gland tissue.
| 2 viruses |
3 viruses |
4 viruses |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Samples positive for ≥ 2 viruses (%)* | Mean virus number/sample | HHV-6B, HHV-7 | HHV-6B, EBV | HHV-6B, VZV | HHV-7, EBV | HHV-7, B19V | HHV-6B, HHV-7, EBV | HHV-6B, HHV-7, B19V | HHV-6B, HHV-7, EBV, B19V | HHV-6B, HHV-7, B19V, MCpyV | |
| IgG4-positive samples, all* (n = 29) |
11 (37.9) | 1.4 | 3 | 1 | 1 | 0 | 0 | 3 | 1 | 2 | 0 |
| Nonspecific sialadenitis (n = 5) | 2 | 1.4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Chronic sclerosing sialadenitis (n = 8) | 3 | 1.6 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Sialolithiasis with sialadenitis (n = 11) | 6 | 1.6 | 3 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Sialolithiasis without sialadenitis (n = 2) | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IgG4 related disease (n = 3) | 0 | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IgG4-negative samples, all* (n = 19) |
8 (42.1) | 1.4 | 4 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 |
| Nonspecific sialadenitis (n = 10) | 6 | 1.6 | 4 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Chronic sclerosing sialadenitis (n = 9) | 2 | 1.1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Healthy salivary gland tissue, all* (n = 13) | 9 (69.2) | 1.8 | 6 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Sialolithiasis without sialadenitis (n = 10) | 6 | 1.7 | 3 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 |
| Healthy glands from neck dissection (n = 3) |
3 | 2.0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
*Due to the low patient numbers, the prevalence percentages are given only to ‘all’, where n = 29 in the IgG4-positive group, n = 19 in the IgG4-negative group, and n = 13 in the group representing healthy salivary gland tissue.